Navigation Links
IRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC)
Date:1/25/2012

reat a broader class of retinal diseases that impacts millions of Americans."

This was the first comparative, prospective evaluation of subvisible MicroPulse laser treatment and anti-VEGF injections in the treatment of CSC with regard to changes in subretinal fluid and visual function. The results indicated superior subretinal fluid resolution for MicroPulse laser compared to anti-VEGF injections, and superior improvement in visual acuity and other visual functions.

(1) Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond) 2011. Advanced online publication

About MicroPulse Technology

MicroPulse is a tissue-sparing laser therapy that works by electronically "chopping" a continuous-wave laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering treatment with less collateral effects than conventional, continuous-wave laser photocoagulation.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, otolaryngology, veterinary, and dermatology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at

SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IRIDEX to Present at the Sidoti & Company New York Micro Cap Conference
2. Cutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit
3. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
4. IRIDEX Signs License and Distribution Agreement with Leader in Eye Care
5. IRIDEX Reports 2011 Third Quarter and Nine-Month Results
6. IRIDEX Announces Third Quarter 2011 Conference Call and Release Date
7. IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market
8. IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO
9. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
10. IRIDEX Expands ENT Laser Applications
11. IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
(Date:5/30/2015)... 30, 2015 “ Milli the Snail ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... game that engages and educates children. , Interactive mobile games ... all the content and games they are playing are doing ...
(Date:5/29/2015)... “In the current environment of opiate ... we provide education that will help practitioners address ... from pain, within the boundaries of the guidelines ... rehabilitation medicine and President/Medical Director of the International ... A new flight of PAINWeekEnd Regional Conferences offers ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the “ ... now offers The Smartest Rheumatologist . The Smartest ... ranging from Fibromyalgia and Osteoporosis, to Arthritis and Gout. ... and Caroline Tredway, editorial head of The Smartest Doc ... on the physicians who participate. Says Tredway, “With so ...
(Date:5/29/2015)... The science of Follicular Unit Extraction (FUE) ... efficient methods of FUE hair transplantation have increased the amount ... most cutting edge hair transplant methods being used to great ... extracting hair from the beard to the scalp. , Most ... male pattern baldness. Beard hair has a life cycle, ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her ... else: God does no wrong. , It’s fitting, then, that ... is titled “God Does No Wrong.” It focuses on what ... tragedy. , “My story has a positive message about ... something productive, something healing,” Howse said. , “God Does No ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Maxim Group,Growth Conference. ... Time on Tuesday, October 7, 2008. Stephen J. ... the company,s business,strategy and historical financial results., ...
... Share Exchange Offer to the Holders of the Following Securities, ... JNJ, The K&N Value Select Corporation offers the holders of ... change into 1 share of,K&N Value Select Corp. - ISIN: CH0006603085 ... October 2008 and ends on 27th November,2008., K&N Value Select ...
... pleased to recognize the Association for Healthcare Resource and Materials ... 5-11. This week is dedicated to acknowledging and celebrating ... healthcare and the overall success of the healthcare supply chain. ... ...
... System To Reduce Claim Fraud and Costs by ... ILOG(R) (Nasdaq:,ILOG, Euronext: ILO, ISIN: FR0004042364) today announced ... in Argentina, is using ILOG,JRules(R) to automate its ... Swiss Medical has been able to reduce,unnecessary medical ...
... often seasonal allergy that affects between 10 and 20 ... a course of patient-adjusted dosing, according to new research ... Head and Neck Surgery. , During the ... allergic rhinitis, was observed in 69 patients, who were ...
... than 1 million children, Stores raise funds for Vitamin ... Quarters found in the,bottom of purses, pockets, and even on ... needy children. The Vitamin Shoppe is asking,everyone to donate their ... a,child., Affecting up to 140 million children every year, ...
Cached Medicine News:Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 2Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 3Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 2Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 3Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: